Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets

This publication has 87 references indexed in Scilit:

• The Concentration of Serum Transforming Growth Factor Beta-1 (TGF-β1) Is Decreased in Cervical Carcinoma Patients
  Cancer Investigation, 2002
• Serum Cytokine Concentrations in Patients with Cervical Cancer: Interleukin-4, Interferon-γ, and Monocyte Chemoattractant Protein-1
  Gynecologic Oncology, 2001
• Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer
  Gynecologic Oncology, 2001
• Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix
  European Journal of Cancer, 1999
• Cytokine Expression by Models of Human Trophoblast as Assessed by a Semiquantitative Reverse Transcription‐Polymerase Chain Reaction Technique
  American Journal of Reproductive Immunology, 1996
• Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation
  Surgery, 1996
• Enhancement of Tumor Growth and Vascular Density by Transfection of Vascular Endothelial Cell Growth Factor Into MCF-7 Human Breast Carcinoma Cells
  JNCI: Journal of the National Cancer Institute, 1995
• Measurement of vascular volume fraction and blood‐tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd‐DTPA enhanced MRI
  Magnetic Resonance in Medicine, 1994
• Thalidomide is an inhibitor of angiogenesis.
  Proceedings of the National Academy of Sciences, 1994
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
  Nature, 1993